Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6211828 | 0.91 | PPARG (0.52) | ESR1POLBMAPTPPARGALDH1A1 | |
| SCHEMBL6210665 | 0.91 | PPARG (0.54) | ESR1POLBMAPTPPARGALDH1A1 | |
| SCHEMBL6212239 | 0.90 | POLB (0.50) | ESR1POLBMAPTPPARGALDH1A1 | |
| SCHEMBL6214403 | 0.89 | ESR1 (0.54) | ESR1POLBMAPTPPARGMEN1 | |
| SCHEMBL6213339 | 0.86 | PIK3CA (0.44) | ALDH1A1THRBMMP13 | |
| SCHEMBL6213391 | 0.78 | PPARG (0.54) | ESR1POLBMAPTPPARGALDH1A1 | |
| SCHEMBL6212062 | 0.76 | MMP13 (0.49) | POLBMAPTPPARGMMP13KDM4E | |
| SCHEMBL6213121 | 0.76 | MMP13 (0.49) | MAPTPPARGALDH1A1THRBL3MBTL1 | |
| SCHEMBL6212605 | 0.75 | PIK3CA (0.46) | MAPTALDH1A1THRBL3MBTL1MAPK1 | |
| SCHEMBL6213639 | 0.75 | ALDH1A1 (0.52) | MAPTALDH1A1TP53L3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362048-B1 | TRIAZOLO COMPOUNDS AS MMP INHIBITORS | WARNER LAMBERT CO (US) | 2005-05-04 | — | — | EP | claimed |
| US-6849637-B2 | Triazolo compounds as MMP inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-02-01 | — | — | US | claimed |
| US-20020151558-A1 | Triazolo compounds as MMP inhibitors | ANDRIANJARA CHARLES (FR) | 2002-10-17 | — | — | US | claimed |
| EP-1531904-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | Warner-Lambert Company LLC (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1362048-B1 | TRIAZOLO COMPOUNDS AS MMP INHIBITORS | WARNER LAMBERT CO (US) | 2005-05-04 | — | — | EP | disclosed |
| US-6849637-B2 | Triazolo compounds as MMP inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2005-01-06 | — | — | US | disclosed |
| US-20040034086-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
| US-20040034085-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| WO-2004007024-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2003-04-24 | — | — | US | disclosed |
| US-20020151558-A1 | Triazolo compounds as MMP inhibitors | ANDRIANJARA CHARLES (FR) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | MMP13, MMP12, MMP25 | ESR1 848/4885POLB 3500/4885MAPT 2826/4885 |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP13, MMP11, MMP10 | ESR1 3851/4885POLB 2444/4885MAPT 1345/4885 |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | MMP13, MMP25, MMP12 | ESR1 935/4885POLB 3286/4885MAPT 2607/4885 |
| US-20040034086-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP11, MMP13, MMP10 | ESR1 3546/4885POLB 2653/4885MAPT 1438/4885 |
| US-20020151558-A1 | Triazolo compounds as MMP inhibitors | MMP8, MMP13, MMP9 | ESR1 4128/4885POLB 1942/4885MAPT 4385/4885 |
| US-20040034085-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP11, MMP13, MMP10 | ESR1 3956/4885POLB 3022/4885MAPT 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.